Form 4: Apimeds Pharmaceuticals US, Inc.: Director Jakap Koo Acquires Stock Options
SEC Form 4 Filing
Director Jakap Koo reports acquisition of stock options in Apimeds Pharmaceuticals US, Inc.
Summary
- On May 16, 2025, Jakap Koo, a director of Apimeds Pharmaceuticals US, Inc., acquired 5,780 stock options with an exercise price of $1.73.
- The options vest fully on May 16, 2026, and expire on May 16, 2035.
- Following the transaction, Koo directly owns 5,780 derivative securities.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock option acquisition. The director's action could be seen as a positive signal, but it's not definitive.
Positives
- The acquisition of stock options by a director could signal confidence in the company's future performance.
Industry Context
Form 4 filings are standard disclosures required by the SEC when insiders, such as directors and officers, trade in their company's stock. This provides transparency to the market.
Stakeholder Impact
- The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 05/16/2025 | Date of transaction: Jakap Koo acquired stock options. |
| 05/16/2026 | Date the options vest in full and become exercisable. |
| 05/16/2035 | Expiration date of the stock options. |
| 05/20/2025 | Date of signature on the Form 4 filing. |
Keywords
stock options, Form 4, director, Apimeds Pharmaceuticals US, Inc., Jakap Koo, acquisition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.